DOP2016000102A - (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso - Google Patents

(aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso

Info

Publication number
DOP2016000102A
DOP2016000102A DO2016000102A DO2016000102A DOP2016000102A DO P2016000102 A DOP2016000102 A DO P2016000102A DO 2016000102 A DO2016000102 A DO 2016000102A DO 2016000102 A DO2016000102 A DO 2016000102A DO P2016000102 A DOP2016000102 A DO P2016000102A
Authority
DO
Dominican Republic
Prior art keywords
aza
bleeding
hereditary
piridopirazolopirimidinonas
indazolopirimidinonas
Prior art date
Application number
DO2016000102A
Other languages
English (en)
Inventor
Karl-Heinz Schlemmer
Michael Sperzel
Joachim Schuhmacher
Yolanda Cancho Grande
Nils Burkhardt
Johannes Köbberling
Maria Köllnberger
Jorma Hassfeld
Christian Stegmann
Manuel Ellermann
Susanne Röhrig
Kristin Bayer
Tom Kinzel
Matthias Werner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2016000102A publication Critical patent/DOP2016000102A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE SOLICITUD SE RELACIONA CON NUEVAS (AZA)PIRIDOPIRAZOLOPIRIMIDINONAS E INDAZOLOPIRIMIDINONAS SUSTITUIDAS, CON PROCESOS PARA SU PREPARACIÓN, EN DONDE LOS COMPUESTOS SE USAN SOLOS O EN COMBINACIONES EN UN MÉTODO PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES, EN PARTICULAR PARA EL TRATAMIENTO Y/O PROFILAXIS DE SANGRADO AGUDO Y RECURRENTE EN PACIENTES CON O SIN TRASTORNOS DE SANGRADO HEREDITARIOS O ADQUIRIDOS SUBYACENTES, EN DONDE EL SANGRADO ESTÁ ASOCIADO CON UNA ENFERMEDAD O INTERVENCIÓN MÉDICA QUE SE ELIGE DEL GRUPO QUE CONSISTE EN MENORRAGIA, HEMORRAGIA POSPARTO, CHOQUE HEMORRÁGICO, TRAUMA, CIRUGÍA, TRASPLANTE, INFARTO, ENFERMEDADES HEPÁTICAS, ANGIOEDEMA HEREDITARIO, SANGRADO DE NARIZ, Y SINOVITIS Y DAÑO DE CARTÍLAGO LUEGO DE HEMARTROSIS.
DO2016000102A 2013-11-05 2016-05-05 (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso DOP2016000102A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13191642 2013-11-05

Publications (1)

Publication Number Publication Date
DOP2016000102A true DOP2016000102A (es) 2016-06-30

Family

ID=49517406

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000102A DOP2016000102A (es) 2013-11-05 2016-05-05 (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso

Country Status (28)

Country Link
US (3) US9598417B2 (es)
EP (1) EP3066100B1 (es)
JP (1) JP6431061B2 (es)
KR (1) KR102312780B1 (es)
CN (1) CN105683194B (es)
AP (1) AP2016009175A0 (es)
AR (1) AR098292A1 (es)
AU (1) AU2014345771B2 (es)
CA (1) CA2929378C (es)
CL (1) CL2016001076A1 (es)
CR (1) CR20160332A (es)
CU (1) CU24361B1 (es)
DO (1) DOP2016000102A (es)
EA (1) EA029373B1 (es)
ES (1) ES2732305T3 (es)
GT (1) GT201600084A (es)
IL (1) IL244645B (es)
MA (1) MA39018A1 (es)
MX (1) MX370419B (es)
PE (1) PE20160934A1 (es)
PH (1) PH12016500828A1 (es)
SG (1) SG11201602133RA (es)
TN (1) TN2016000161A1 (es)
TW (1) TWI657089B (es)
UA (1) UA117504C2 (es)
UY (1) UY35809A (es)
WO (1) WO2015067549A1 (es)
ZA (1) ZA201602311B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
PE20170920A1 (es) * 2014-11-03 2017-07-12 Bayer Pharma AG Piperidinilpirazolopirimidinonas y utilizacion de las mismas
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors
WO2017007917A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN110590673A (zh) * 2019-09-02 2019-12-20 南通大学 一种4-氯-7-甲基-1h-吲唑及其化学合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
EP4289850A4 (en) * 2021-02-05 2024-12-11 Scinnohub Pharmaceutical Co., Ltd Plasmin inhibitor, preparation method therefor, and application thereof
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022261154A1 (en) 2021-06-09 2022-12-15 Eli Lilly And Company Substituted fused azines as kras g12d inhibitors
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof
US20250302837A1 (en) 2022-04-05 2025-10-02 Socpra Sciences Santé Et Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192559A5 (en) * 1972-07-17 1974-02-08 Ugine Kuhlmann Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs
JP5205053B2 (ja) 2004-07-30 2013-06-05 フェリング ビー.ブイ. トラネキサム酸製剤
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
CN102056922B (zh) * 2008-06-06 2013-11-20 赛诺菲-安万特 作为tafia抑制剂的大环脲和磺酰胺衍生物
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
KR101675607B1 (ko) 2009-04-07 2016-11-11 에머리티 파마 아베 치료제로서 이소옥사졸-3(2h)-온 유사체
WO2012047156A1 (en) * 2010-10-04 2012-04-12 Astrazeneca Ab Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases
BR112013011737A2 (pt) * 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
WO2012082947A1 (en) * 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
CA2821777A1 (en) * 2010-12-16 2012-06-21 Bayer Intellectual Property Gmbh Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors

Also Published As

Publication number Publication date
MA39018A1 (fr) 2017-06-30
HK1223940A1 (zh) 2017-08-11
EP3066100A1 (en) 2016-09-14
CL2016001076A1 (es) 2016-12-09
ZA201602311B (en) 2017-08-30
EA201690935A1 (ru) 2016-10-31
KR20160079093A (ko) 2016-07-05
TWI657089B (zh) 2019-04-21
CU24361B1 (es) 2018-10-04
GT201600084A (es) 2017-07-12
AU2014345771A1 (en) 2016-04-14
UY35809A (es) 2015-05-29
KR102312780B1 (ko) 2021-10-15
US9598417B2 (en) 2017-03-21
AR098292A1 (es) 2016-05-26
EP3066100B1 (en) 2019-04-17
NZ718100A (en) 2021-06-25
US20170239251A1 (en) 2017-08-24
CN105683194A (zh) 2016-06-15
IL244645A0 (en) 2016-04-21
PE20160934A1 (es) 2016-10-08
TN2016000161A1 (en) 2017-10-06
US10098883B2 (en) 2018-10-16
ES2732305T3 (es) 2019-11-21
AU2014345771B2 (en) 2018-09-13
UA117504C2 (uk) 2018-08-10
EA029373B1 (ru) 2018-03-30
US10668071B2 (en) 2020-06-02
CN105683194B (zh) 2018-09-14
TW201609728A (zh) 2016-03-16
US20180344739A1 (en) 2018-12-06
CR20160332A (es) 2016-11-10
PH12016500828A1 (en) 2016-06-13
AP2016009175A0 (en) 2016-04-30
SG11201602133RA (en) 2016-05-30
JP2016535052A (ja) 2016-11-10
IL244645B (en) 2019-06-30
JP6431061B2 (ja) 2018-11-28
WO2015067549A1 (en) 2015-05-14
MX2016005969A (es) 2016-08-11
US20150126449A1 (en) 2015-05-07
CA2929378C (en) 2021-12-07
CA2929378A1 (en) 2015-05-14
MX370419B (es) 2019-12-11

Similar Documents

Publication Publication Date Title
DOP2016000102A (es) (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
IL262591A (en) Methods for treating patients with familial hypercholesterolemia
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CR11731A (es) Composiciones y procedimientos para su preparación y uso
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2019007555A (es) Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.
BR112017020013A2 (pt) método para preparação de um substituto da pele, substituto da pele, substituto dérmico, enxerto, enxerto para uso, e kit para implementação do método
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
UY36385A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas